Neurocrine Biosciences: Still a Solid Investment Opportunity After 30% Price Surge Since Last Coverage

Neurocrine Biosciences' stock has risen 30% since my last coverage. Despite this, I still recommend a "Buy" due to a contrarian trade opportunity. The company's strong pipeline, particularly for its schizophrenia treatment, and potential for a positive Phase 3 trial outcome, justify the investment. Additionally, the recent FDA approval of the company's Tourette's treatment provides further momentum.